TRCT
SNDX icon

Tower Research Capital (TRC)’s Syndax Pharmaceuticals SNDX Stock Holding History

Tower Research Capital (TRC)’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$337K Buy
14,432
+9,588
+198% +$208K 0.01% 1212
2025
Q4 		$102K Sell
4,844
-8,396
-63% -$146K ﹤0.01% 1934
2025
Q3 		$204K Buy
13,240
+4,760
+56% +$62.3K 0.01% 1443
2025
Q2 		$79.4K Buy
8,480
+4,308
+103% +$47.4K ﹤0.01% 2568
2025
Q1 		$51.3K Sell
4,172
-14,018
-77% -$198K ﹤0.01% 2216
2024
Q4 		$240K Buy
18,190
+11,681
+179% +$200K ﹤0.01% 1592
2024
Q3 		$125K Sell
6,509
-9,146
-58% -$189K ﹤0.01% 2056
2024
Q2 		$321K Buy
15,655
+14,998
+2,283% +$314K 0.01% 1709
2024
Q1 		$15.6K Sell
657
-2,629
-80% -$58.6K ﹤0.01% 3229
2023
Q4 		$71K Sell
3,286
-7,825
-70% -$120K ﹤0.01% 2901
2023
Q3 		$161K Buy
11,111
+3,581
+48% +$67.7K 0.01% 1588
2023
Q2 		$158K Buy
7,530
+4,374
+139% +$91.1K 0.01% 1725
2023
Q1 		$67K Sell
3,156
-1,791
-36% -$44.6K ﹤0.01% 2246
2022
Q4 		$126K Sell
4,947
-2,288
-32% -$53.4K 0.01% 1648
2022
Q3 		$174K Buy
7,235
+1,490
+26% +$33.4K ﹤0.01% 2062
2022
Q2 		$111K Buy
5,745
+3,434
+149% +$57.2K ﹤0.01% 2200
2022
Q1 		$40K Sell
2,311
-4,782
-67% -$80.5K ﹤0.01% 2909
2021
Q4 		$155K Buy
7,093
+2,192
+45% +$40.5K ﹤0.01% 1951
2021
Q3 		$94K Sell
4,901
-907
-16% -$15.1K ﹤0.01% 2455
2021
Q2 		$100K Buy
5,808
+4,467
+333% +$81.8K ﹤0.01% 2427
2021
Q1 		$30K Buy
1,341
+246
+22% +$5.56K ﹤0.01% 3569
2020
Q4 		$24K Sell
1,095
-15,949
-94% -$331K ﹤0.01% 3754
2020
Q3 		$252K Buy
17,044
+13,064
+328% +$199K ﹤0.01% 2342
2020
Q2 		$59K Buy
+3,980
New +$60.6K ﹤0.01% 2923
2019
Q4 		– Sell
-748
Closed -$6K – 4289
2019
Q3 		$6K Sell
748
-229
-23% -$2.09K ﹤0.01% 3243
2019
Q2 		$9K Sell
977
-4,486
-82% -$32.7K ﹤0.01% 2629
2019
Q1 		$29K Buy
5,463
+948
+21% +$5.41K ﹤0.01% 2072
2018
Q4 		$20K Buy
+4,515
New +$24.8K ﹤0.01% 1948
2018
Q3 		– Sell
-1,804
Closed -$13K – 4208
2018
Q2 		$13K Buy
+1,804
New +$17.7K ﹤0.01% 2673
2017
Q4 		– Sell
-2,961
Closed -$35K – 3978
2017
Q3 		$35K Buy
+2,961
New +$36.3K ﹤0.01% 2302
2017
Q1 		– Sell
-3,547
Closed -$26K – 3849
2016
Q4 		$26K Buy
+3,547
New +$38.9K ﹤0.01% 1918
2016
Q3 		– Sell
-253
Closed -$2K – 4379
2016
Q2 		$2K Sell
253
-610
-71% -$8.36K ﹤0.01% 3960
2016
Q1 		$11K Buy
+863
New +$10.8K ﹤0.01% 1878

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Tower Research Capital (TRC)'s SNDX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Syndax Pharmaceuticals (SNDX) stake by 198% in Q1 2026, buying an estimated $208K and bringing the position to 14,432 shares worth $337K. The position accounts for 0.01% of the portfolio, ranked #1212.

Tower Research Capital (TRC) first reported a position in SNDX in Q1 2016 and has held it in 33 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Tower Research Capital (TRC) held 14,432 shares of Syndax Pharmaceuticals worth $337K as of Q1 2026.
  • Tower Research Capital (TRC) bought 9,588 Syndax Pharmaceuticals shares in Q1 2026, an estimated $208K.
  • Syndax Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1212 holding.
  • Tower Research Capital (TRC) first reported a position in Syndax Pharmaceuticals in Q1 2016 and has held it in 33 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.